SCHEMBL12374077

SCHEMBL12374077

O=[N+]([O-])c1ccc(Br)nc1Oc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 7/20 0.57
MERTK Q12866 1/20 0.50
RAB9A P51151 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 2/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
TTR P02766 1/20 0.44
ALB P02768 1/20 0.44
THRB P10828 1/20 0.44
ALDH1A1 P00352 4/20 0.41
MAPT P10636 5/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TXNRD1 Q16881 1/20 0.39
MAPK1 P28482 2/20 0.39
S1PR4 O95977 1/20 0.39
S1PR1 P21453 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12374079 0.81 PIN1 (0.57) PIN1MERTKRAB9AMEN1KMT2A
SCHEMBL21494712 0.79 PIN1 (0.55) PIN1MERTKRAB9AMEN1KMT2A
SCHEMBL1029176 0.77 MERTK (0.48) MERTKRAB9ATDP1ALDH1A1MAPT
SCHEMBL31104588 0.77 MERTK (0.48) MERTKRAB9ATDP1ALDH1A1MAPT
SCHEMBL29674894 0.74 PIN1 (0.56) PIN1MERTKRAB9AMEN1KMT2A
SCHEMBL242653 0.74 KMT2A (0.74) PIN1RAB9AMEN1KMT2ANPC1
SCHEMBL11036294 0.74 PIN1 (0.56) PIN1MERTKRAB9AMEN1KMT2A
SCHEMBL12620328 0.73 PIN1 (1.00) PIN1MERTKMAPT
SCHEMBL28029112 0.72 ALDH1A1 (0.37) MEN1KMT2AATMTDP1ALDH1A1
Diphenylether SCHEMBL27974940 0.72 LTA4H (0.55) PIN1RAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110200535-A1 DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110200535-A1 DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT GABRA6, GABRA4, GABRA1 PIN1 3534/4885MERTK 1024/4885RAB9A 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.